Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TYK-00540 + enzalutamide
- Development stage
- Phase 2
- Lead developer
- TYK Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**TYK-00540 + enzalutamide** is an investigational combination therapy for advanced/metastatic solid tumors, specifically metastatic castration-resistant prostate cancer (mCRPC). TYK-00540 is a novel, selective small molecule inhibitor targeting cyclin-dependent kinase 2, 4, and 6 (CDK2/4/6), developed by TYK Medicines, intended to inhibit tumor cell growth and overcome resistance to other CDK inhibitors. Enzalutamide (brand name Xtandi) is an approved, second-generation nonsteroidal antiandrogen that acts as an antagonist of the androgen receptor, blocking androgen signaling and inhibiting prostate cancer progression. The combination aims to enhance antitumor efficacy by simultaneously targeting cell cycle progression (via CDK2/4/6 inhibition) and androgen signaling (via androgen receptor inhibition) in patients with mCRPC who have progressed on prior hormonal therapies.
- Other names
- enzalutamideTYK-00540TYK00540TYK 00540TY-0540TY0540TY 0540
02
Targets
AR (Adrenergic receptors)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on TYK-00540 + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TYK-00540 + enzalutamide.